Gan Danan, Xu Aili, Du Hongbo, Ye Yong'an
Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5 Haiyuncang Street, Dongcheng District, Beijing 100700, China.
Department of Gastroenterology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing 100102, China.
Evid Based Complement Alternat Med. 2017;2017:9012929. doi: 10.1155/2017/9012929. Epub 2017 Aug 24.
This aim is to evaluate the effect of Sijunzi decoction (SJZD) treating chronic atrophic gastritis (CAG).
We performed searches in seven databases. The randomized controlled trials (RCTs) comparing SJZD with standard medical care or inactive intervention for CAG were enrolled. Combined therapy of SJZD plus conventional therapies compared with conventional therapies alone was also retrieved. The primary outcome included the incidence of gastric cancer and the improvement of atrophy, intestinal metaplasia, and dysplasia based on the gastroscopy and pathology. The secondary outcomes were clearance rate, quality of life, and adverse event/adverse drug reaction.
Six RCTs met the inclusion criteria. The research quality was low in the trials. For the overall effect rate, pooled analysis from 4 trials showed that modified SJZD plus conventional medications exhibited a significant improvement (OR = 4.86; 95% CI: 2.80 to 8.44; < 0.00001) and without significant heterogeneity compared with the conventional medications alone. None reported the adverse effect.
Modified SJZD combined with conventional western medicines appears to have benefits for CAG. Due to the limited number and methodological flaw, the beneficial and harmful effects of SJZD for CAG could not be identified. More high-quality clinical trials are needed to confirm the results.
本研究旨在评估四君子汤(SJZD)治疗慢性萎缩性胃炎(CAG)的效果。
我们在七个数据库中进行了检索。纳入比较SJZD与标准医疗护理或针对CAG的无活性干预措施的随机对照试验(RCT)。还检索了SJZD联合传统疗法与单纯传统疗法的联合治疗。主要结局包括胃癌发病率以及基于胃镜检查和病理的萎缩、肠化生和发育异常的改善情况。次要结局为清除率、生活质量以及不良事件/药物不良反应。
六项RCT符合纳入标准。试验的研究质量较低。对于总有效率,来自4项试验的汇总分析表明,加味四君子汤联合传统药物与单纯传统药物相比有显著改善(OR = 4.86;95% CI:2.80至8.44;P < 0.00001),且无显著异质性。均未报告不良反应。
加味四君子汤联合传统西药似乎对CAG有益。由于数量有限和方法学缺陷,无法确定四君子汤对CAG的有益和有害影响。需要更多高质量的临床试验来证实结果。